Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16405045 | 1.00 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1ALDH1A1TSHR | |
| SCHEMBL8090957 | 1.00 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1ALDH1A1TSHR | |
| SCHEMBL21993869 | 0.87 | SLC1A3 (0.34) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9716580 | 0.85 | SLC1A3 (0.33) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3902508 | 0.77 | ALDH1A1 (0.33) | ALDH1A1TSHRNFKB1THPOHSD17B10 | |
| SCHEMBL14813150 | 0.76 | — | — | |
| SCHEMBL319703 | 0.76 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12505764 | 0.76 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12807367 | 0.74 | — | — | |
| SCHEMBL11383067 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225297-A1 | Process for preparing chiral diphosphines | RHODIA CHIMIE | 2003-12-04 | — | — | US | disclosed |
| US-6610875-B1 | Forming bidentate ligands ofr assymetric catalysts; bromina-ting diaryldiol; esterifying with sulfonic acid; substituting cyano for bromine groups; coupling with a dicyclophosphine | RHODIA CHIMIE (FR) | 2003-08-26 | — | — | US | disclosed |
| EP-1153031-A1 | METHOD FOR PREPARING CHIRAL DIPHOSPHINES | RHODIA CHIMIE (FR) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049028-A1 | METHOD FOR PREPARING CHIRAL DIPHOSPHINES | RHODIA CHIMIE (FR) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225297-A1 | Process for preparing chiral diphosphines | CYP1A1, NR5A1, AR | SLC1A3 4801/4885SLC1A2 4414/4885SLC1A1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.